Halozyme Therapeutics (HALO) News Today → Reclusive millionaire’s final warning about America (From Weiss Ratings) (Ad) Free halo Stock Alerts $49.66 +0.16 (+0.32%) (As of 06/17/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative June 18 at 4:38 AM | marketbeat.comVirtu Financial LLC Acquires New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Virtu Financial LLC acquired a new stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 16,421 shares of the biophaJune 16 at 9:13 PM | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Position Raised by Congress Asset Management Co. MACongress Asset Management Co. MA grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 15.6% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 351,076 shares of the biopharmaceutical company's stock after purchasJune 15 at 4:00 PM | investorplace.comThe 3 Best Healthcare Stocks to Buy in June 2024June 15 at 5:32 AM | americanbankingnews.comMatthew L. Posard Sells 10,000 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) StockJune 14, 2024 | insidertrades.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Director Sells $500,100.00 in StockJune 14, 2024 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) and Evaxion Biotech A/S (NASDAQ:EVAX) Financial ContrastJune 14, 2024 | americanbankingnews.comHalozyme Therapeutics, Inc. Forecasted to Earn Q2 2024 Earnings of $0.68 Per Share (NASDAQ:HALO)June 13, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Director Matthew L. Posard Sells 10,000 SharesHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) Director Matthew L. Posard sold 10,000 shares of the company's stock in a transaction dated Tuesday, June 11th. The shares were sold at an average price of $50.01, for a total transaction of $500,100.00. Following the sale, the director now directly owns 109,755 shares in the company, valued at $5,488,847.55. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.June 13, 2024 | marketbeat.comQ2 2024 EPS Estimates for Halozyme Therapeutics, Inc. Decreased by Zacks Research (NASDAQ:HALO)Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Stock analysts at Zacks Research dropped their Q2 2024 earnings per share estimates for Halozyme Therapeutics in a research note issued on Monday, June 10th. Zacks Research analyst A. Chakraborty now anticipates that the biopharmaceuticalJune 12, 2024 | marketbeat.comFirst Light Asset Management LLC Sells 179,486 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)First Light Asset Management LLC decreased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 57.2% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The fund owned 134,050 shares of the biopharmaceutical company's stocJune 12, 2024 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Shares Gap Down to $50.85June 11, 2024 | insidermonkey.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Downgraded by Piper SandlerJune 11, 2024 | marketbeat.comPrudential PLC Takes Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Prudential PLC acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 33,773 shares of the bJune 11, 2024 | americanbankingnews.comLeerink Partnrs Weighs in on Halozyme Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:HALO)June 10, 2024 | marketbeat.comQ2 2024 EPS Estimates for Halozyme Therapeutics, Inc. Increased by Leerink Partnrs (NASDAQ:HALO)Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Stock analysts at Leerink Partnrs raised their Q2 2024 earnings per share (EPS) estimates for Halozyme Therapeutics in a research note issued on Friday, June 7th. Leerink Partnrs analyst D. Risinger now anticipates that the biopharmaceuticJune 8, 2024 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Downgraded by Piper Sandler to NeutralJune 8, 2024 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) PT Raised to $58.00June 8, 2024 | americanbankingnews.comHalozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High at $51.00June 7, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Sectoral Asset Management Inc.Sectoral Asset Management Inc. lowered its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 95.9% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,030 shares of the biopharmaJune 7, 2024 | seekingalpha.comHalozyme Therapeutics: The Story BrightensJune 7, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) PT Raised to $58.00 at Wells Fargo & CompanyWells Fargo & Company lifted their target price on Halozyme Therapeutics from $48.00 to $58.00 and gave the stock an "overweight" rating in a report on Friday.June 7, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Cut to Neutral at Piper SandlerPiper Sandler downgraded shares of Halozyme Therapeutics from an "overweight" rating to a "neutral" rating and boosted their target price for the company from $48.00 to $51.00 in a research note on Friday.June 6, 2024 | benzinga.comHalozyme's ENHANZE Product Gets New Patent Grant in EUJune 6, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Sets New 12-Month High at $51.00Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month High at $51.00June 6, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Releases FY24 Earnings GuidanceHalozyme Therapeutics (NASDAQ:HALO) updated its FY24 earnings guidance. The company provided EPS guidance of $3.65-4.05 for the period, compared to the consensus estimate of $3.71.June 6, 2024 | prnewswire.comHalozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial OutlookJune 6, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Acquired by Hsbc Holdings PLCHsbc Holdings PLC grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 27.7% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,101 shares of the biopharmaceutical company's stock after buyingJune 5, 2024 | prnewswire.comHalozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery PlatformJune 4, 2024 | prnewswire.comHalozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 3, 2024 | marketbeat.comStephens Investment Management Group LLC Grows Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Stephens Investment Management Group LLC boosted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 4.4% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,518,455 shares of the biopharmaceutical company's stock after puJune 2, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Given Average Rating of "Moderate Buy" by BrokeragesHalozyme Therapeutics, Inc. (NASDAQ:HALO - Get Free Report) has received an average recommendation of "Moderate Buy" from the six brokerages that are currently covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and five have issued a buy recoJune 1, 2024 | marketbeat.comEvoke Wealth LLC Makes New $1.36 Million Investment in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Evoke Wealth LLC purchased a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 36,657 shares of the biopharmaceutical cMay 31, 2024 | stocknews.com4 Biotech Stocks Ready to Surge in JuneMay 30, 2024 | marketbeat.comTD Asset Management Inc Increases Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)TD Asset Management Inc grew its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 517.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,983,916 shares of the biopharmacMay 28, 2024 | marketbeat.comDimensional Fund Advisors LP Raises Stock Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Dimensional Fund Advisors LP increased its holdings in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 9.9% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,613,113 shares of theMay 27, 2024 | marketbeat.comBernzott Capital Advisors Reduces Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Bernzott Capital Advisors decreased its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 27.3% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 124,979 shares of the biopharmaceutical company's stMay 25, 2024 | marketbeat.comOntario Teachers Pension Plan Board Buys 19,882 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Ontario Teachers Pension Plan Board lifted its stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 137.5% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 34,346 shares of the biopharmaceutical company's stMay 23, 2024 | insidertrades.comInsider Selling: Halozyme Therapeutics, Inc. (NASDAQ:HALO) SVP Sells 10,000 Shares of StockMay 22, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Given Buy Rating at HC WainwrightHC Wainwright restated a "buy" rating and set a $50.00 price objective on shares of Halozyme Therapeutics in a research report on Wednesday.May 21, 2024 | marketbeat.comAssenagon Asset Management S.A. Has $2.15 Million Holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Assenagon Asset Management S.A. cut its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 57.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 52,840 shares of the biopharmaMay 21, 2024 | markets.businessinsider.comHalozyme: Bristol Myers Gets New PDUFA Date For Subcutaneous Nivolumab Co-Formulated With ENHANZEMay 21, 2024 | prnewswire.comHalozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE®May 20, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Stake Lowered by GW&K Investment Management LLCGW&K Investment Management LLC cut its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 5.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,226,538 shares of the biopharmaceutical company'sMay 19, 2024 | marketbeat.comHalozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Purchased by Mizuho Markets Americas LLCMizuho Markets Americas LLC grew its position in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.9% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 446,661 shares of tMay 18, 2024 | marketbeat.comWafra Inc. Acquires 23,811 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Wafra Inc. grew its holdings in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 79.2% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 53,877 shares of the biopharmaceutical company's stock after purchasing an addiMay 17, 2024 | marketbeat.comInternational Assets Investment Management LLC Buys New Stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO)International Assets Investment Management LLC bought a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) during the fourth quarter, according to its most recent disclosure with the SEC. The firm bought 27,868 shares of the biopharmaceutical company's stock, valued at approximateMay 16, 2024 | finance.yahoo.comHalozyme Therapeutics Stock Earns IBD Stock Rating Upgrade, Hitting 80-Plus RS RatingMay 16, 2024 | marketbeat.comBoston Partners Purchases 468,977 Shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO)Boston Partners increased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 562.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 552,392 shares of the biopharmaceutical company'sMay 14, 2024 | marketbeat.comHalozyme Therapeutics (NASDAQ:HALO) Hits New 52-Week High at $45.15Halozyme Therapeutics (NASDAQ:HALO) Hits New 1-Year High at $45.15May 13, 2024 | marketbeat.comSwiss National Bank Decreases Position in Halozyme Therapeutics, Inc. (NASDAQ:HALO)Swiss National Bank decreased its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) by 10.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 260,000 shares of the biopharmaceutical company's Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address why 99.94% won’t make you money (Ad)I believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them. Click here to download my options trading cheat sheet (5-7 stocks inside here) HALO Media Mentions By Week HALO Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. HALO News Sentiment▼0.680.91▲Average Medical News Sentiment HALO News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. HALO Articles This Week▼186▲HALO Articles Average Week Get Halozyme Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: TWST News Today IOVA News Today RLAY News Today ADPT News Today FATE News Today ALLO News Today KOD News Today ALNY News Today BMRN News Today NBIX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:HALO) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredInflation Is Robbing You Blind! Here’s How to Fight Back!Quietly, inflation has reduced your purchasing power by 29.4% since 2014. So something that cost $100 in 20...American Alternative | SponsoredUnexpected twist to Trump’s trialUnexpected Twist to Trump's Trial Most folks sense there's more to the Trump trial than meets the eye. B...Stansberry Research | Sponsored